Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.
Mind Cure Health will be focus its psychedelics R&D on psilocybin, ketamine and ibogaine. The Company will pursue both pain-based and mental health applications.
The Psychedelics Revolution. One part changing social attitudes. One part medical necessity. One part hard economics.
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.
In a "bad" year for the emerging cannabis industry, global cannabis sales rose by 48% in 2019. That's not bad.
The U.S. Food and Drug Administration is claiming that CBD poses significant risks to the human liver. Nonsense.
As the U.S. Cannabis Revolution unfolds, over 90% of Americans now want cannabis legalized (at least) for medical purposes. Attention Congress.
The new cannabis store licensing system has commenced in Ontario. Total retail cannabis stores could multiply by nearly a factor of 10 in 2020.